Clinical Trial News and Research

RSS

Platelet-derived growth factor-BB restores function in rats with Parkinson's disease

Few treatments for Parkinson's disease (PD) restore function for extended periods. In a new study published today in the inaugural issue of the Journal of Parkinson's Disease, an international group of researchers report that platelet-derived growth factor-BB (PDGF-BB) restored function in rodents and shows promise as a clinical candidate drug for treatment of PD.

10 Jun 2011

Neoprobe's Lymphoseek Phase 3 trial data presented at SNM annual meeting

Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, today announced that full results from the NEO3-05 study, demonstrating Lymphoseek met all primary and secondary endpoints in intraoperative lymphatic mapping (ILM) procedures.

10 Jun 2011

FDA grants Fast Track Designation for Emergent BioSolutions' NuThrax vaccine

Emergent BioSolutions Inc. announced today that its investigational anthrax vaccine, NuThrax, has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA).

10 Jun 2011

ASI announces successful completion of $10 million round of financing

Access Scientific, Inc. (ASI) today announced the successful completion of a $10 million round of financing. The round was led by CAC and further supported by the company's previous institutional investors.

9 Jun 2011

ImmunoCellular expands ICT-107 Phase II clinical trial for glioblastoma multiforme

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, today announced the expansion of sites for its Phase II clinical trial of ICT-107. ICT-107 is the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme (GBM).

9 Jun 2011

Repligen total revenue increases 30% to $27,291,000 for fiscal year 2011

Repligen Corporation today reported results for the fourth quarter and fiscal year 2011, ended March 31, 2011.

9 Jun 2011

U.S. FDA announces safety label changes for cholesterol-lowering medication, simvastatin

The U.S. Food and Drug Administration today is announcing safety label changes for the cholesterol-lowering medication simvastatin because the highest approved dose--80 milligram (mg)--has been associated with an elevated risk of muscle injury or myopathy, particularly during the first 12 months of use.

9 Jun 2011

Neurologix reports new results from NLX-P101 Phase 2 trial against Parkinson's disease

Neurologix, Inc. announced today several new results from the Company's successful Phase 2 clinical trial for its novel, investigational gene therapy NLX-P101 for the treatment of Parkinson's disease (PD) as part of a comprehensive presentation of study findings to the National Institutes of Health (NIH) Recombinant DNA Advisory Committee.

9 Jun 2011

Scientists, advocacy experts form new international Foundation for Vaccine Research

Fourteen leading scientists and advocacy experts in vaccines and infectious diseases have announced the formation of a new international Foundation to advance and accelerate vaccine research and development against infectious diseases.

9 Jun 2011

FDA accepts Adamis IND for APC-100 to treat prostate cancer

Adamis Pharmaceuticals Corporation announced today that the FDA has accepted an Investigational New Drug (IND) application for APC-100 to treat prostate cancer (PCa).

9 Jun 2011

Isotechnika reports consolidated net loss of $2.9 million for first quarter 2011

Isotechnika Pharma Inc. today announced financial and operating results for the three months ended March 31, 2011.

9 Jun 2011

ICU patients should wait a week before receiving intravenous feeding: New study

Patients in the intensive care unit who do not tolerate adequate nutrition from tube feeding should wait a week before receiving intravenous (IV) feeding because, compared with early IV feeding, it enhances recovery from critical illness.

8 Jun 2011

Intercell, Merck terminate V710 Phase II/III trial against S. aureus infection

Merck, known as MSD outside the United States and Canada, and Intercell AG (VSE: ICLL) today announced that following a detailed analysis of the data from the Phase II/III clinical trial evaluating V710, an investigational vaccine for the prevention of Staphylococcus aureus (S. aureus) infection, the independent Data Monitoring Committee (DMC) has unanimously recommended termination of the study.

8 Jun 2011

Rosa, Profil Institute partner to offer simulation technology for diabetes and obesity clinical trials

Profil Institute for Clinical Research, Inc., a company leading the industry in early phase clinical trials for diabetes and obesity, and Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, jointly announced today a strategic alliance to offer Profil Institute customers use of Rosa's modeling technology to simulate disease physiology, drug action, patient variability, and trial outcomes for their early phase clinical development programs.

8 Jun 2011

Pharmasset expands PSI-7977 clinical trial for treatment of chronic hepatitis C

Pharmasset, Inc. announced today the addition of three treatment cohorts to the ELECTRON trial of PSI-7977, a nucleotide analog polymerase inhibitor, for the treatment of chronic hepatitis C (HCV).

8 Jun 2011

Quest conducts first clinical Investigators Meeting for Oregovomab in Rome, provides corporate updates

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, announced today that it conducted its first clinical Investigators Meeting for Oregovomab in Rome, Italy.

8 Jun 2011

Two-year, $150,000 award to study implementation of electronic health records

A researcher in the University of Cincinnati (UC) Department of Emergency Medicine has received a two-year, $150,000 fellowship award from the Emergency Medicine Foundation to study the implementation of electronic health records in a suburban emergency department (ED).

8 Jun 2011

Topline results from 4SC vidofludimus Phase IIb trial against rheumatoid arthritis

4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced topline results from its randomised, double-blind, placebo-controlled Phase IIb clinical trial COMPONENT in RA.

8 Jun 2011

Cabozantinib shows early promise in treatment of prostate cancer spread to the bone

A new drug to treat prostate cancer shows early promise, particularly against tumors that have spread to the bone, a multi-site study shows.

8 Jun 2011

MSU professor to lead acetazolamide clinical trial on idiopathic intracranial hypertension

A rare but increasingly more common disease striking overweight, younger women is the focus of a clinical trial at Michigan State University, where an osteopathic physician is testing the effectiveness of a certain drug against a potentially blindness-causing ailment.

8 Jun 2011

Clinical Trial News and Research

Platelet-derived growth factor-BB restores function in rats with Parkinson's disease

Neoprobe's Lymphoseek Phase 3 trial data presented at SNM annual meeting

FDA grants Fast Track Designation for Emergent BioSolutions' NuThrax vaccine

ASI announces successful completion of $10 million round of financing

ImmunoCellular expands ICT-107 Phase II clinical trial for glioblastoma multiforme

Repligen total revenue increases 30% to $27,291,000 for fiscal year 2011

U.S. FDA announces safety label changes for cholesterol-lowering medication, simvastatin

Neurologix reports new results from NLX-P101 Phase 2 trial against Parkinson's disease

Scientists, advocacy experts form new international Foundation for Vaccine Research

FDA accepts Adamis IND for APC-100 to treat prostate cancer

Isotechnika reports consolidated net loss of $2.9 million for first quarter 2011

ICU patients should wait a week before receiving intravenous feeding: New study

Intercell, Merck terminate V710 Phase II/III trial against S. aureus infection

Rosa, Profil Institute partner to offer simulation technology for diabetes and obesity clinical trials

Pharmasset expands PSI-7977 clinical trial for treatment of chronic hepatitis C

Quest conducts first clinical Investigators Meeting for Oregovomab in Rome, provides corporate updates

Two-year, $150,000 award to study implementation of electronic health records

Topline results from 4SC vidofludimus Phase IIb trial against rheumatoid arthritis

Cabozantinib shows early promise in treatment of prostate cancer spread to the bone

MSU professor to lead acetazolamide clinical trial on idiopathic intracranial hypertension

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

BFEB: Advances in microplate-based assays and analysis

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery